News | December 21, 2024
Lonza expands capsule manufacturing capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Subscribe To Our Newsletter & Stay Updated
